result microdystrophin patient
solid dmd microdystrophin data consist previou disclosur fall
short competitor solid report microdystrophin express
patient enrol high dose result consist
seen first two patient high dose result
fall short competitor sarepta report mean microdystrophin express via
blot report averag minidystrophin
patient high dose cohort addit solid provid specif
clinic hold program remov leav program timelin question
model chang limit runway could result solid fall
behind competitor expens larg in-lin compani
cash expect fund oper earli expect solid need
fortifi balanc sheet year expect challeng consid
current environ clinic hold drug yet produc result
clearli suggest compar differenti efficaci rel competitor program
furthermor believ weak balanc sheet posit like limit solid flexibl
build manufactur could delay timelin rel competitor
updat model base expens ep vs old
risk under-perform thesi includ posit clinic regulatori financi
develop disappoint updat competitor program
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
clinic stage biotechnolog compani focus
develop therapi treat duchenn muscular dystrophi dmd
compani lead product candid gene therapi clinic
develop treat dmd
blue sky scenario assum probabl success
dmd gene therapi market share
grey sky scenario reflect stock trade cash
event fail clinic develop
 close
compani mention price
martin auster certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
